The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Identifieur interne : 000218 ( Main/Corpus ); précédent : 000217; suivant : 000219The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Auteurs : Mark R. CooksonSource :
- Nature Reviews Neuroscience [ 1471-003X ] ; 2010-12.
Abstract
Parkinson's disease, like many common age-related conditions, is now recognized to have a substantial genetic component. Here, I discuss how mutations in a large complex gene — leucine-rich repeat kinase 2 (LRRK2) — affect protein function, and I review recent evidence that LRRK2 mutations affect pathways that involve other proteins that have been implicated in Parkinson's disease, specifically α-synuclein and tau. These concepts can be used to understand disease processes and to develop therapeutic opportunities for the treatment of Parkinson's disease.
Url:
DOI: 10.1038/nrn2935
Links to Exploration step
ISTEX:2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease</title><author><name sortKey="Cookson, Mark R" sort="Cookson, Mark R" uniqKey="Cookson M" first="Mark R." last="Cookson">Mark R. Cookson</name><affiliation><mods:affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health (NIH), Building 35, Room 1A116, MSC 3707, 35 Convent Drive, Bethesda, 20982-3707, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: Cookson@mail.nih.gov</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1038/nrn2935</idno><idno type="url">https://api.istex.fr/document/2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000218</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease</title><author><name sortKey="Cookson, Mark R" sort="Cookson, Mark R" uniqKey="Cookson M" first="Mark R." last="Cookson">Mark R. Cookson</name><affiliation><mods:affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health (NIH), Building 35, Room 1A116, MSC 3707, 35 Convent Drive, Bethesda, 20982-3707, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: Cookson@mail.nih.gov</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Nature Reviews Neuroscience</title><idno type="ISSN">1471-003X</idno><idno type="eISSN">1471-0048</idno><imprint><publisher>Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</publisher><date type="published" when="2010-12">2010-12</date><biblScope unit="volume">11</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="791">791</biblScope><biblScope unit="page" to="797">797</biblScope></imprint><idno type="ISSN">1471-003X</idno></series><idno type="istex">2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9</idno><idno type="DOI">10.1038/nrn2935</idno><idno type="ArticleID">nrn2935</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1471-003X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">Parkinson's disease, like many common age-related conditions, is now recognized to have a substantial genetic component. Here, I discuss how mutations in a large complex gene — leucine-rich repeat kinase 2 (LRRK2) — affect protein function, and I review recent evidence that LRRK2 mutations affect pathways that involve other proteins that have been implicated in Parkinson's disease, specifically α-synuclein and tau. These concepts can be used to understand disease processes and to develop therapeutic opportunities for the treatment of Parkinson's disease.</div></front></TEI><istex><corpusName>nature</corpusName><author><json:item><name>Mark R. Cookson</name><affiliations><json:string>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health (NIH), Building 35, Room 1A116, MSC 3707, 35 Convent Drive, Bethesda, 20982-3707, USA</json:string><json:string>E-mail: Cookson@mail.nih.gov</json:string></affiliations></json:item></author><language><json:string>eng</json:string></language><abstract>Parkinson's disease, like many common age-related conditions, is now recognized to have a substantial genetic component. Here, I discuss how mutations in a large complex gene — leucine-rich repeat kinase 2 (LRRK2) — affect protein function, and I review recent evidence that LRRK2 mutations affect pathways that involve other proteins that have been implicated in Parkinson's disease, specifically α-synuclein and tau. These concepts can be used to understand disease processes and to develop therapeutic opportunities for the treatment of Parkinson's disease.</abstract><qualityIndicators><score>7.472</score><pdfVersion>1.6</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>560</abstractCharCount><pdfWordCount>6321</pdfWordCount><pdfCharCount>41670</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>81</abstractWordCount></qualityIndicators><title>The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease</title><genre><json:string>other</json:string></genre><host><volume>11</volume><pages><total>7</total><last>797</last><first>791</first></pages><issn><json:string>1471-003X</json:string></issn><issue>12</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1471-0048</json:string></eissn><title>Nature Reviews Neuroscience</title></host><categories><wos><json:string>NEUROSCIENCES</json:string></wos></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1038/nrn2935</json:string></doi><id>2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</publisher><availability><p>NATURE</p></availability><date>2010</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease</title><author><persName><forename type="first">Mark R.</forename><surname>Cookson</surname></persName><email>Cookson@mail.nih.gov</email><note type="biography">Mark R. Cookson is a senior investigator at the National Institute on Aging (NIA), Bethesda, Maryland, USA. He is a cell biologist whose current research interests include the effects of mutations in the genes associated with neurodegeneration at the cellular and molecular levels. His laboratory efforts are directed at finding the underlying pathways that lead to Parkinson's disease and related disorders. He received both his B.Sc. and Ph.D. degrees from the University of Salford, UK in 1991 and 1995, respectively. His postdoctoral studies included time spent at the Medical Research Council laboratories and at the University of Newcastle, UK. He joined the Mayo Clinic, Jacksonville, Florida, USA, as an assistant professor in 2000 and moved to the NIA in February 2002. Within the Laboratory of Neurogenetics, his group works on the effects of mutations associated with Parkinson's disease on protein function.</note><affiliation>Mark R. Cookson is a senior investigator at the National Institute on Aging (NIA), Bethesda, Maryland, USA. He is a cell biologist whose current research interests include the effects of mutations in the genes associated with neurodegeneration at the cellular and molecular levels. His laboratory efforts are directed at finding the underlying pathways that lead to Parkinson's disease and related disorders. He received both his B.Sc. and Ph.D. degrees from the University of Salford, UK in 1991 and 1995, respectively. His postdoctoral studies included time spent at the Medical Research Council laboratories and at the University of Newcastle, UK. He joined the Mayo Clinic, Jacksonville, Florida, USA, as an assistant professor in 2000 and moved to the NIA in February 2002. Within the Laboratory of Neurogenetics, his group works on the effects of mutations associated with Parkinson's disease on protein function.</affiliation><affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health (NIH), Building 35, Room 1A116, MSC 3707, 35 Convent Drive, Bethesda, 20982-3707, USA</affiliation></author></analytic><monogr><title level="j">Nature Reviews Neuroscience</title><idno type="pISSN">1471-003X</idno><idno type="eISSN">1471-0048</idno><imprint><publisher>Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</publisher><date type="published" when="2010-12"></date><biblScope unit="volume">11</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="791">791</biblScope><biblScope unit="page" to="797">797</biblScope></imprint></monogr><idno type="istex">2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9</idno><idno type="DOI">10.1038/nrn2935</idno><idno type="ArticleID">nrn2935</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Parkinson's disease, like many common age-related conditions, is now recognized to have a substantial genetic component. Here, I discuss how mutations in a large complex gene — leucine-rich repeat kinase 2 (LRRK2) — affect protein function, and I review recent evidence that LRRK2 mutations affect pathways that involve other proteins that have been implicated in Parkinson's disease, specifically α-synuclein and tau. These concepts can be used to understand disease processes and to develop therapeutic opportunities for the treatment of Parkinson's disease.</p></abstract></profileDesc><revisionDesc><change when="2010-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus nature" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//NPG//DTD XML Article//EN" URI="NPG_XML_Article.dtd" name="istex:docType"></istex:docType><istex:document><article id="nrn2935" language="eng" origsrc="yes" publish="issue" relation="no"><entity-declarations><entity id="figf1" url="/nrn/journal/v11/n12/images/nrn2935-f1.jpg"></entity><entity id="figf2" url="/nrn/journal/v11/n12/images/nrn2935-f2.jpg"></entity></entity-declarations><!--nrn2935--><pubfm><jtl>Nature Reviews Neuroscience</jtl><vol>11</vol><iss>12</iss><idt>201012</idt><categ id="pr"></categ><pp><spn>791</spn><epn>797</epn><cnt>7</cnt></pp><issn type="print">1471-003X</issn><issn type="electronic">1471-0048</issn><cpg><cpy>2010</cpy><cpn>Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</cpn></cpg><doi>10.1038/nrn2935</doi></pubfm><fm><atl display="show">The role of leucine-rich repeat kinase 2 (<i>LRRK2</i>) in Parkinson's disease</atl><aug><au><fnm>Mark R.</fnm><snm>Cookson</snm><inits>M R</inits><orf rid="a1"></orf><bio><p>Mark R. Cookson is a senior investigator at the National Institute on Aging (NIA), Bethesda, Maryland, USA. He is a cell biologist whose current research interests include the effects of mutations in the genes associated with neurodegeneration at the cellular and molecular levels. His laboratory efforts are directed at finding the underlying pathways that lead to Parkinson's disease and related disorders. He received both his B.Sc. and Ph.D. degrees from the University of Salford, UK in 1991 and 1995, respectively. His postdoctoral studies included time spent at the Medical Research Council laboratories and at the University of Newcastle, UK. He joined the Mayo Clinic, Jacksonville, Florida, USA, as an assistant professor in 2000 and moved to the NIA in February 2002. Within the Laboratory of Neurogenetics, his group works on the effects of mutations associated with Parkinson's disease on protein function.</p></bio></au><aff><oid id="a1"></oid>Mark R. Cookson is at the <org>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health (NIH)</org>, <street>Building 35, Room 1A116, MSC 3707, 35 Convent Drive</street>, <cty>Bethesda</cty>, <st>Maryland</st><zip>20982-3707</zip>, <cny>USA</cny>. <newline></newline><email>Cookson@mail.nih.gov</email></aff></aug><hst><pubdate day="19" month="11" type="aop" year="2010"></pubdate></hst><websumm>Recent evidence suggests that mutations in <i>LRRK2</i> are linked to Parkinson's disease. In this Progress article, Mark Cookson discusses how these mutations might affect LRRK2 function and its interactions with other proteins that have been implicated in Parkinson's disease, specifically α-synuclein and tau.</websumm><abs><p>Parkinson's disease, like many common age-related conditions, is now recognized to have a substantial genetic component. Here, I discuss how mutations in a large complex gene — leucine-rich repeat kinase 2 (<i>LRRK2</i>) — affect protein function, and I review recent evidence that <i>LRRK2</i> mutations affect pathways that involve other proteins that have been implicated in Parkinson's disease, specifically α-synuclein and tau. These concepts can be used to understand disease processes and to develop therapeutic opportunities for the treatment of Parkinson's disease.</p></abs></fm></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="eng"><title>The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease</title></titleInfo><titleInfo type="alternative" lang="eng" contentType="CDATA"><title>The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Mark R.</namePart><namePart type="family">Cookson</namePart><affiliation>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health (NIH), Building 35, Room 1A116, MSC 3707, 35 Convent Drive, Bethesda, 20982-3707, USA</affiliation><affiliation>E-mail: Cookson@mail.nih.gov</affiliation><role><roleTerm type="text">author</roleTerm></role><description>Mark R. Cookson is a senior investigator at the National Institute on Aging (NIA), Bethesda, Maryland, USA. He is a cell biologist whose current research interests include the effects of mutations in the genes associated with neurodegeneration at the cellular and molecular levels. His laboratory efforts are directed at finding the underlying pathways that lead to Parkinson's disease and related disorders. He received both his B.Sc. and Ph.D. degrees from the University of Salford, UK in 1991 and 1995, respectively. His postdoctoral studies included time spent at the Medical Research Council laboratories and at the University of Newcastle, UK. He joined the Mayo Clinic, Jacksonville, Florida, USA, as an assistant professor in 2000 and moved to the NIA in February 2002. Within the Laboratory of Neurogenetics, his group works on the effects of mutations associated with Parkinson's disease on protein function.</description></name><typeOfResource>text</typeOfResource><genre type="other" displayLabel="Progress"></genre><originInfo><publisher>Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</publisher><dateIssued encoding="w3cdtf">2010-12</dateIssued><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">Parkinson's disease, like many common age-related conditions, is now recognized to have a substantial genetic component. Here, I discuss how mutations in a large complex gene — leucine-rich repeat kinase 2 (LRRK2) — affect protein function, and I review recent evidence that LRRK2 mutations affect pathways that involve other proteins that have been implicated in Parkinson's disease, specifically α-synuclein and tau. These concepts can be used to understand disease processes and to develop therapeutic opportunities for the treatment of Parkinson's disease.</abstract><relatedItem type="host"><titleInfo><title>Nature Reviews Neuroscience</title></titleInfo><identifier type="ISSN">1471-003X</identifier><identifier type="eISSN">1471-0048</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>791</start><end>797</end><total>7</total></extent></part></relatedItem><identifier type="istex">2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9</identifier><identifier type="DOI">10.1038/nrn2935</identifier><identifier type="ArticleID">nrn2935</identifier><accessCondition type="use and reproduction" contentType="copyright">©2010 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.</accessCondition><recordInfo><recordContentSource>NATURE</recordContentSource><recordIdentifier>/nrn/journal/v11/n12/images/nrn2935-f1.jpg</recordIdentifier><recordIdentifier>/nrn/journal/v11/n12/images/nrn2935-f2.jpg</recordIdentifier></recordInfo></mods></metadata><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9/annexes/jpeg</uri></json:item><json:item><original>true</original><mimetype>application/vnd.ms-powerpoint</mimetype><extension>ppt</extension><uri>https://api.istex.fr/document/2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9/annexes/ppt</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">NEUROSCIENCES</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000218 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000218 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:2A6E61C69AE50BC4A223D63F1A96E7BD0A5A40C9
|texte= The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |